EGFR and non-small cell lung carcinoma: The seminal discovery that activating mutations in EGFR are associated with pronounced clinical responsiveness to EGFR tyrosine kinase inhibitors (EGFR-TKI) delineated the era of precision oncology approaches for the treatment of NSCLC (6, 7).